ASPI targets $300–$700M EBITDA by 2031 on global scaling

ASPI says it is transitioning from development to global scaling, targeting $300–$700 million EBITDA by 2031 via expansion across radiopharmaceuticals, isotope enrichment, helium/LNG, and nuclear fuel.